iCAD is a provider of image analysis and workflow solutions that enable healthcare professionals to identify pathologies and pinpoint cancer earlier. In addition, iCAD commercializes the intra-operative Axxent® electronic brachytherapy (eBx™) system. Due to a slow launch of the Axxent system, the stock declined throughout 2011, leading to an undesirable cost of capital at a time when the company needed to raise additional growth capital.